From Aristos Innovation Consulting we want to congratulate our client GlyCardial Diagnostics SL (GlyCardial), for having won phase 2 of the SME Instrument in the call of October, the last of 2018, with its AGLYC project.
AGLYC is an IVD device, as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage.
Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage. And, considering that cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in recent years, AGLYC is a step forward in saving the lives of thousands of people throughout the world.
The project will begin at the beginning of 2019 and will last 24 months.
We are very happy to have been part of GlyCardial’s success. After having helped them with the preparation of the proposal for the SME Instrument Phase 1, where they received funding on the first attempt, we have once more achieved a Phase 2 together on the first attempt. And both grants within 2018, a record!
We wish our GlyCardial client the best of luck in its development!
Follow us on twitter.